𧬠Tissue repair is essentialābut what happens when it doesnāt switch off? An interesting perspective on how persistent inflammation and repair programmes contribute to fibrosis, and where we might intervene.
#Immunology #Fibrosis

𧬠Tissue repair is essentialābut what happens when it doesnāt switch off? An interesting perspective on how persistent inflammation and repair programmes contribute to fibrosis, and where we might intervene.
#Immunology #Fibrosis
Breaking: Semaglutide (Wegovy) becomes the first GLP-1 receptor agonist approved to treat metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-a⦠#Drugapproval #Fibrosis #GLP1agonists #Hepatology #Liverdisease #Drugapproval #Fibrosis #GLP1agonists #Hepatology #Liverdisease ā¦
Zhang et al. identify RalA-dependent signaling as a regulator of age-related #skeletalmuscle dysfunction. The novel compound UA-30 inhibits RalA activity, reduces muscle #fibrosis, improves mitochondrial function & mobility, & extends health span & survival in mice. rupress.org/jem/article/...
BCL9 drives the MerTKāERKāSPP1 macrophage M2 program in #PulmonaryFibrosis, while its inhibition reprograms macrophageāfibroblast crosstalk toward fibroblast #Lipogenesis, supports AT2 cell expansion and attenuates #Fibrosis.
Exciting news! My groupās new in press preview is in @insight.jci.org insight.jci.org/articles/vie.... Detailed analysis of endothelial plasticity and characteristation of fibrosis-associated EC (FAEC) phenotypes in healthy tissue, models of liver fibrosis and MSALD patients. #EndMT #fibrosis
š We are pleased to welcome our speakers for the Main Session āImmunity in the Intestineā. www.immunology-conference.de
@efis-immunology.bsky.social @iuis-online.bsky.social @dgfi-yi.bsky.social
#immunology26 #dgfi #ImmunityInTheIntestine #Microbiome #Fibrosis #Inflammation #Immunology
Commentary: An NFATC4 phospho-switch links matrix stiffness to fibroblast fate: doi.org/10.1172/JCI2...
Rebecca Shelley Frabottaā& Purushothama Rao Tata @dukemedschool.bsky.social discuss Kadri et al.: doi.org/10.1172/JCI1...
#Fibrosis
Breaking: Semaglutide (Wegovy) becomes the first GLP-1 receptor agonist approved to treat metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-a⦠#Drugapproval #Fibrosis #GLP1agonists #Hepatology #Liverdisease #Drugapproval #Fibrosis #GLP1agonists #Hepatology #Liverdisease ā¦